Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Satiation hormone could increase risk of diabetes, heart attack and breast cancer in women

One of the body’s satiation hormones, neurotensin, could raise women’s risk of suffering one of three common and serious conditions: diabetes, cardiovascular disease and breast cancer.

There is also a connection between the hormone and premature death in women, especially from cardiovascular disease.

The findings have been presented in a study from Lund University in Sweden, published in the Journal of the American Medical Association.

“It was surprising to find such a clear link to the risk of type 2 diabetes and cardiovascular disease as well as to breast cancer. Obesity is a common risk factor for all three conditions, but the connection with neurotensin is not explained by obesity or other known risk factors”, says Professor Olle Melander from the Department of Clinical Sciences at Lund University, who is also a consultant at Skåne University Hospital.

“This is the first time a satiation hormone has been linked to these three common diseases in women. It therefore opens up a new field for continued research on risk assessment and preventive treatment”, says Professor Marju Orho-Melander from the Department of Clinical Sciences at Lund University, one of the authors of the study.

It is interesting that the findings apply specifically to women. In the case of breast cancer this is obvious, but a better understanding of the development of cardiovascular disease in women is greatly needed.

The connection between neurotensin and these conditions in women was seen to be so strong that it has a clear impact on the patient’s life expectancy. The strong connection also means it is appropriate to use neurotensin as a clinical risk marker for the conditions, in the view of the researchers. This provides new opportunities for early identification of women who are likely to develop cardiovascular disease, which cannot be predicted with the current known risk factors. This makes it possible to initiate preventive treatment at an early stage.

“Because the hormone circulates around the body in the blood, levels can be measured with a normal blood test, which is an advantage”, explains Olle Melander.

The results were obtained through analysis of blood samples from over 4 600 people who took part in the Swedish population study Malmö Diet and Cancer. The participants gave blood samples over several years and the researchers saw a link between the level of neurotensin and the women who went on to develop one of the three diseases.

A low-fat diet reduces neurotensin production and could therefore be one way to regulate neurotensin levels, believe Olle Melander and Marju Orho-Melander. However, they point out that if neurotensin is to work as a target for treatment, a causal relationship must first be established. They hope to be able to identify this relationship through genetic studies that are currently underway.

About neurotensin
The hormone neurotensin is produced both in the intestine and in the brain, and circulates in the blood.

The hormone has known functions in pain and digestion in the gastrointestinal tract. The link to satiation was only discovered a few years ago. Previous studies have shown that injecting animals with neurotensin affects how much they eat.

For more information
Olle Melander, Professor of Internal Medicine, Department of Clinical Sciences in Malmö, Lund University, and consultant, Internal Medicine Clinic, Skåne University Hospital, +46 704 54 68 20, +46 40 39 12 09,

Marju Orho-Melander, Professor of Diabetes and Cardiovascular Disease – Genetic Epidemiology, Department of Clinical Sciences in Malmö, Lund University, +46 707 39 82 89, +46 40 39 12 10,

Referenslänk: Jama, the Journal of the American Medical Association.
Original Contribution | October 10, 2012
Plasma Proneurotensin and Incidence of Diabetes, Cardiovascular Disease, Breast Cancer, and Mortality

Olle Melander, MD, PhD; Alan S. Maisel, MD; Peter Almgren, MSc; Jonas Manjer, MD, PhD; Mattias Belting, MD, PhD; Bo Hedblad, MD, PhD; Gunnar Engström, MD, PhD; Ute Kilger, PhD; Peter Nilsson, MD, PhD; Andreas Bergmann, PhD; Marju Orho-Melander, PhD

Helga Ekdahl Heun | idw
Further information:

More articles from Health and Medicine:

nachricht NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases

nachricht Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Locomotion control with photopigments

Researchers from Göttingen University discover additional function of opsins

Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...

Im Focus: Surveying the Arctic: Tracking down carbon particles

Researchers embark on aerial campaign over Northeast Greenland

On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...

Im Focus: Unique Insights into the Antarctic Ice Shelf System

Data collected on ocean-ice interactions in the little-researched regions of the far south

The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...

Im Focus: ILA 2018: Laser alternative to hexavalent chromium coating

At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.

When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...

Im Focus: Radar for navigation support from autonomous flying drones

At the ILA Berlin, hall 4, booth 202, Fraunhofer FHR will present two radar sensors for navigation support of drones. The sensors are valuable components in the implementation of autonomous flying drones: they function as obstacle detectors to prevent collisions. Radar sensors also operate reliably in restricted visibility, e.g. in foggy or dusty conditions. Due to their ability to measure distances with high precision, the radar sensors can also be used as altimeters when other sources of information such as barometers or GPS are not available or cannot operate optimally.

Drones play an increasingly important role in the area of logistics and services. Well-known logistic companies place great hope in these compact, aerial...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

International Virtual Reality Conference “IEEE VR 2018” comes to Reutlingen, Germany

08.03.2018 | Event News

Latest News

Wandering greenhouse gas

16.03.2018 | Earth Sciences

'Frequency combs' ID chemicals within the mid-infrared spectral region

16.03.2018 | Physics and Astronomy

Biologists unravel another mystery of what makes DNA go 'loopy'

16.03.2018 | Life Sciences

Science & Research
Overview of more VideoLinks >>>